DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

876 Varmus H, eds. The Molecular Basis of Blood Diseases, 3rd
ed. WB Saunders Co., Philadelphia, 2001, pp. 740–763.
Mackman N, Taubman M. Tissue factor: Past, present, and
future. Arterioscler Thromb Vasc Biol, 2009, 29:1986–1988.
Mann KG, Butenas S, Brummel K. The dynamics of thrombin
formation. Arterioscler Thromb Vasc Biol, 2003, 23:17–25.
McClain MR, Palomaki GE, Piper M, et al. A rapid-ACCE
review of CYP2C9 and VKORC1 alleles testing to inform
warfarin dosing in adults at elevated risk for thrombotic events
to avoid serious bleeding. Genet Med, 2008, 10:89–98.
Moll S, Ortel TL. Monitoring warfarin therapy in patients with
lupus anticoagulants. Ann Intern Med, 1997, 127:177–185.
Mutucumarana VP, Acher F, Straight DL, et al. A conserved
region of human vitamin K-dependent carboxylase between
residues 398 and 404 is important for its interaction with the
glutamate substrate. J Biol Chem, 2003, 278:46488–46493.
Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant
function by generating new interaction sites (exosites)
for blood clotting proteinases. Trends Cardiovasc Med, 2002,
12:331–338.
Patrono C, Bachmann F, Baigent C, et al. European Society of
Cardiology. Expert consensus document on the use of antiplatelet
agents. The task force on the use of antiplatelet agents in patients
with atherosclerotic cardiovascular disease of the European
Society of Cardiology. Eur Heart J, 2004, 25:166–181.
Porto I, Giubilato S, DeMaria GL, et al. Platelet P2Y12 receptor
inhibition by thienopyridines: Status and future. Expert
Opin Investig Drugs, 2009, 18:1317–1332.
Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation
defect in hemophilia and in jaundice. Am J Med Sci,
1935, 190:501–511.
Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes
on transcriptional regulation and warfarin dose. N Engl
J Med, 2005, 352:2293–2295.
Rishavy MA, Pudota BN, Hallgren KW, et al. A new model for
vitamin K-dependent carboxylation: The catalytic base that
deprotonates vitamin K hydroquinone is not Cys but an activated
amine. Proc Natl Acad Sci U S A, 2004, 101:13732–13737.
Rosen HN, Maitland LA, Suttie JW, et al. Vitamin K and maintenance
of skeletal integrity in adults. Am J Med, 1993, 94:62–68.
Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1
cause warfarin resistance and multiple coagulation factor deficiency
type 2. Nature, 2004, 427:537–541.
Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extendedrelease
dipyridamole versus clopidogrel for recurrent stroke. N
Engl J Med, 2008, 359:1238–1251.
Sadowski JA, Hood SJ, Dallal GE, Garry PJ. Phylloquinone in
plasma from elderly and young adults: Factors influencing its
concentration. Am J Clin Nutr, 1989, 50:100–108.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug
dose, and bleeding risk in warfarin-treated patients: A HuGEnet
systematic review and meta-analysis. Genet Med, 2005,
7:97–104.
Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological
activity of the active metabolite of clopidogrel. Thromb
Haemost, 2000, 84:891–896.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus
warfarin in the treatment of acute venous thromboembolism.
N Engl J Med, 2009, December 6 [Epub ahead of print].
Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants
of response to warfarin during initial anticoagulation.
N Engl J Med, 2008, 358:999–1008.
Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia.
A contemporary clinical approach to diagnosis and
management. Chest, 2009, 135:1651–1664.
Shapiro AD, Jacobson LJ, Armon ME, et al. Vitamin K deficiency
in the newborn infant: Prevalence and perinatal risk factors.
J Pediatr, 1986, 109:675–680.
Sugahara K, Kitagawa H. Heparin and heparan sulfate biosynthesis.
IUBMB Life, 2002, 54:163–175.
Vert P, Deblay MF. Hemorrhagic disorders in infants of epileptic
mothers. In: Janz D, Bossi L, Daum M, et al., eds. Epilepsy,
Pregnancy, and the Child. Raven Press, New York, 1982, pp.
387–388.
Wajih N, Sane DC, Hutson SM, Wallin R. The inhibitory effect
of calumenin on the vitamin K-dependent γ-carboxylation system.
Characterization of the system in normal and warfarinresistant
rats. J Biol Chem, 2004, 279:25276–25283.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel
in patients with acute coronary syndromes. N Engl J
Med, 2009, 361:1045–1057.
Warkentin TE. Heparin-induced thrombocytopenia. Hematol
Oncol Clin North Am, 2007, 21:589–607.
Warner ED, Brinkhous KM, Smith HP. Bleeding tendency of
obstructive jaundice: Prothrombin deficiency and dietary factors.
Proc Soc Exp Biol Med, 1938, 37:628–630.
Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable
Angina to Prevent Recurrent Events Trial Investigators. Effects
of clopidogrel in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. N Engl J Med,
2001, 345:494–502.
Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant
effect of warfarin as evaluated in rabbits by selective
depression of individual procoagulant vitamin K-dependent
clotting factors. J Clin Invest, 1993, 92:2131–2140.